JP7803087B2 - Iron compound-containing composition - Google Patents

Description

The present invention relates to an oral liquid composition containing plant placenta extract, which can be used in the fields of pharmaceuticals, quasi-drugs, foods, etc.

Although iron is an essential metal for living organisms, it has been reported that iron intake tends to be deficient relative to the recommended intake, especially in women. The Dietary Reference Intakes for Japanese (2020 edition) recommends 10.5 mg of iron for women, but the 2018 National Health and Nutrition Survey found that women's iron intake was 7.5 mg, resulting in a daily iron deficiency of approximately 3 mg (Non-Patent Document 1). Drinks and supplements containing iron compounds have been used as an efficient dietary intake method, but iron compounds react with other ingredients, impairing flavor and quality (Patent Documents 1 and 2).
In recent years, beauty drinks containing placenta extract have become increasingly popular. Animal placenta extracts, which are made from mammalian placentas, are extracts extracted from the placentas of mammals such as pigs, cows, horses, humans, and sheep. Mammalian placental tissues are rich in amino acids, active peptides, vitamins, minerals, sugars, enzymes, nucleic acids, and other nutrients essential for fetal growth (Patent Document 3). Because animal placenta extracts have a unique taste and odor, masking techniques have been reported for their consumption as beverages (Patent Document 4).

Meanwhile, in recent years, the term placenta has come to refer to materials that have similar functions and nutrients to the placenta, and a prime example of this is plant placenta extract, which is made from plant placenta. Plant placenta is rich in nutrients that help seeds germinate, such as amino acids, vitamins, and minerals (Patent Document 5).

While there are several oral liquid compositions containing plant placenta on the market, there is still room for further development.

Food and Development Vol. 55 No. 6 P. 41 Japanese Patent Application Laid-Open No. 2017-93397 Japanese Patent Application Laid-Open No. 2000-279143 JP 2011-160742 A JP 2018-166443 A JP 2014-224081 A

The inventors discovered that when plant placenta extract was incorporated into an oral liquid composition, a precipitate formed. From the perspective of commercial viability, such as appearance and texture, the formation of precipitate should be suppressed as much as possible; however, to date, no method has been reported for suppressing the formation of precipitate derived from plant placenta extract when incorporated into an oral liquid composition.

The objective of the present invention is to provide an oral liquid composition that suppresses the formation of precipitation derived from plant placenta extract.

The inventors conducted extensive research to solve this problem and unexpectedly discovered that adding an iron compound in an amount of 0.006 w/v% or more (equivalent to iron) and collagen peptides could suppress precipitation, leading to the completion of the present invention.

The present invention has been made based on these findings and has the following aspects.
(1) An oral liquid composition containing a plant placenta extract, an iron compound, and a collagen peptide, wherein the content of the iron compound is 0.006 to 0.2 w/v% in terms of iron;
(2) The oral liquid composition according to (1), wherein the iron compound is at least one selected from the group consisting of ferrous fumarate, ferric chloride, iron citrate, ammonium ferrous citrate, sodium ferrous citrate, ferrous gluconate, iron lactate, ferrous pyrophosphate, ferric pyrophosphate, ferrous sulfate, and heme iron.
(3) The oral liquid composition according to (1) or (2), wherein the content of the plant placenta extract is 0.001 to 4 w/v%.
(4) The oral liquid composition according to any one of (1) to (3), wherein the content of the plant placenta extract is 0.008 to 32 w/v% in terms of placenta.
(5) The oral liquid composition according to any one of (1) to (4), wherein the collagen peptide content is 0.02 to 20 w/v%.
(6) The oral liquid composition according to any one of (1) to (5), having a pH of 2.5 to 4.5.
(7) The oral liquid composition according to any one of (1) to (6), wherein the oral liquid composition is a liquid beverage.
(8) A method of suppressing precipitation caused by blending plant placenta extract by blending an iron compound and a collagen peptide.
is.

The present invention makes it possible to provide an oral liquid composition that contains plant placenta extract and suppresses precipitation.

The plant placenta of the present invention is the part inside the ovary of a plant that contains ovules, and its origin is not particularly limited, but examples include rose, morning glory, lotus, camellia, soybean, barley, rye, corn, okra, cucumber, tomato, watermelon, acerola, aloe, melon, chili pepper, bitter melon, etc., with melon being preferred.
The plant placenta extract of the present invention can be extracted with a solvent such as water, a lower aliphatic alcohol (e.g., methanol, ethanol, isopropyl alcohol), a polyhydric alcohol (e.g., 1,3-butylene glycol, propylene glycol, dipropylene glycol, glycerin), a lower aliphatic ketone (e.g., acetone), or a mixture of the above solvents, and the form of the extract is not particularly limited. Furthermore, commercially available products such as "Rose Placenta" (Ginza Tomato Co., Ltd.) and "Plant Placenta (Melon Placenta)" (Koei Kogyo Co., Ltd.) may also be used as the plant placenta extract.

The content of the plant placenta extract of the present invention in the oral liquid composition of the present invention is preferably 0.001 to 4 w/v%, and more preferably 0.02 to 2 w/v%. Furthermore, the content, calculated as placenta, is preferably 0.008 to 32 w/v%, and more preferably 0.16 to 16 w/v%.

In addition, from the perspective of the effects of the present invention, the content of plant placenta extract is preferably 0.1 to 1,000 parts by mass, and more preferably 2 to 200 parts by mass, per 1 part by mass of iron, calculated as iron.

In the present invention, examples of "iron compounds" include ferrous fumarate, ferric chloride, ferrous citrate, ammonium ferrous citrate, sodium ferrous citrate, ferrous gluconate, ferrous lactate, ferrous pyrophosphate, ferric pyrophosphate, ferrous sulfate, and heme iron.

In terms of the effects of the present invention, the content of the iron compound in the oral liquid composition is preferably 0.006 to 0.2 w/v%, and more preferably 0.006 to 0.04 w/v%, calculated as iron. Furthermore, the content of the iron compound is preferably 0.03 to 2.0 w/v%, more preferably 0.03 to 1.2 w/v%, even more preferably 0.03 to 0.5 w/v%, and most preferably 0.03 to 0.3 w/v%.

In the present invention, the "collagen peptide" is not particularly limited in terms of its origin, and may be synthetic, or may be collagen peptide produced by extraction from by-products such as hide, bone, ligament, tendon, and cartilage produced when processing livestock such as cows and pigs, or fish; however, collagen peptide derived from pigs is preferred. Collagen peptide obtained by decomposing collagen protein using enzymes or chemical treatment is preferred. The average molecular weight of the collagen peptide is not particularly limited, but is preferably 500 to 50,000, and more preferably 1,000 to 25,000. The collagen peptide of the present invention may be a commercially available product, such as "Nippi Peptide PS-1" (manufactured by Nippi Co., Ltd.), "Nippi Peptide PRA-P" (manufactured by Nippi Co., Ltd.), "Nippi Peptide FCP-EX" (manufactured by Nippi Co., Ltd.), "HACP-CF" (manufactured by Jellice Co., Ltd.), "HACP-TF" (manufactured by Jellice Co., Ltd.), "Colapep PU" (manufactured by Nitta Gelatin Co., Ltd.), "Colapep JB" (manufactured by Nitta Gelatin Co., Ltd.), "HDL-50SP" (manufactured by Nitta Gelatin Co., Ltd.), "SCP-3100" (manufactured by Nitta Gelatin Co., Ltd.), and "peptan P2000HD" (manufactured by Rousselot Co., Ltd.).

The content of collagen peptide in the oral liquid composition of the present invention is preferably 0.02 to 20 w/v%, more preferably 0.2 to 15 w/v%.

In terms of the effects of the present invention, the content of collagen peptide, in iron equivalent, is preferably 0.1 to 4,000 parts by mass per part by mass of iron, more preferably 0.5 to 4,000 parts by mass, even more preferably 5 to 1,500 parts by mass, and most preferably 20 to 1,500 parts by mass.

The present invention can suppress the formation of precipitates derived from plant placenta extract by combining iron compounds and collagen peptides.

The oral liquid composition of the present invention is not particularly limited as long as it is a liquid that can be taken orally, and examples thereof include pharmaceuticals, quasi-drugs, and foods (including not only general foods but also foods with nutrient functions and foods for specified health uses). Pharmaceuticals and quasi-drugs include, for example, oral liquid preparations and energy drinks. Foods include soft drinks, carbonated drinks, sports and functional drinks, non-alcoholic drinks, milk drinks, tea drinks, coffee drinks, fruit and vegetable drinks, jelly drinks, and more. More preferably, pharmaceuticals and quasi-drugs include oral liquid preparations and energy drinks, and foods include various beverages such as foods with nutrient functions and foods for specified health uses, carbonated drinks, and jelly drinks.

The pH of the oral liquid composition of the present invention is not particularly limited, but from the viewpoint of palatability, it is preferably 2.5 to 4.5, and more preferably 3.0 to 4.0. To maintain the pH within the above range, a pH adjuster such as an organic acid can be added as necessary.

The oral liquid composition of the present invention can be produced by a conventional method, and the method is not particularly limited. Typically, the oral liquid composition is obtained by weighing out each component, dissolving it in an appropriate amount of purified water, stirring, adjusting the pH, adding more purified water to adjust the volume, and filtering and sterilizing the resulting mixture as necessary.

The oral liquid composition of the present invention can also contain other ingredients such as vitamins, minerals, amino acids and their salts, herbal medicines, herbal extracts, caffeine, royal jelly, dextrin, etc., as appropriate, provided that the effects of the present invention are not impaired. Furthermore, if necessary, additives such as antioxidants, colorants, flavorings, flavoring agents, preservatives, sweeteners, and acidulants can also be added as appropriate, provided that the effects of the present invention are not impaired.

The present invention will be explained in more detail below with reference to examples and comparative examples.

(Comparative Example 1, Example 1, Comparative Example 2-2, Examples 2-1, 2-2, Comparative Example 3, Example 3, Comparative Example 5, Example 5)
First, citric acid and sodium benzoate were dissolved in purified water, and the volume was adjusted to approximately 60% of the total volume with purified water to obtain an acidulant solution. Next, ferrous ammonium citrate was dissolved in purified water, and the volume was adjusted to 0.4% iron to obtain an iron solution. To the acidulant solution, an iron solution or iron compound was added as needed to obtain the formulation shown in the table. Melon placenta-derived plant placenta extract (Plant Placenta (Melon Placenta), Water Extract, manufactured by Koei Kogyo Co., Ltd.) and porcine-derived collagen peptide (Colapep JB, manufactured by Nitta Gelatin Co., Ltd.) were added, and purified water was added to approximately 90% of the total volume and thoroughly stirred. After thorough stirring, the pH was adjusted using hydrochloric acid or sodium hydroxide, and purified water was added to the total volume to obtain an oral liquid composition. 50 ml of these oral liquid compositions were filled into screw tubes No. 7 (manufactured by Maruemu Co., Ltd.) and sterilized at 80°C for 25 minutes. An oral liquid composition without added ferrous ammonium citrate and collagen peptide served as a control.

(Comparative Example 2-1, Example 2-3, Comparative Example 3, Comparative Example 4, Examples 4-1 to 4-7)
First, citric acid and sodium benzoate were dissolved in purified water, and the volume was adjusted to about 60% of the total volume with purified water to obtain an acidulant solution. Next, ammonium iron citrate was dissolved in purified water, and the volume was adjusted to contain 0.4% iron to obtain an iron solution. Furthermore, citric acid, sodium benzoate, and porcine collagen peptide (Collapep JB, manufactured by Nitta Gelatin Co., Ltd.) were dissolved in purified water to obtain a collagen solution. Melon placenta-derived plant placenta extract (Plant Placenta (Melon Placenta), Water Extract, manufactured by Koei Kogyo Co., Ltd.) was weighed into a beaker, and acidulant solution, collagen solution, iron solution or iron compound, and collagen peptide were added as needed to obtain the formulation shown in the table. Purified water was added to about 90% of the total volume and thoroughly stirred. After thorough stirring, the pH was adjusted using hydrochloric acid or sodium hydroxide, and purified water was added to the total volume to obtain an oral liquid composition. These oral liquid compositions were placed in screw tubes No. 50 ml of the composition was filled into a jar No. 7 (manufactured by Maruemu Co., Ltd.) and sterilized at 80° C. for 25 minutes. An oral liquid composition to which neither ammonium iron citrate nor collagen peptide was added was used as a control.
In Example 4-6, sodium ferrous citrate was added instead of ammonium iron citrate, and in Example 4-7, fish-derived collagen peptide (Nippi Peptide FCP-EX, manufactured by Nippi Corporation) was added instead of pig-derived collagen peptide (Collapep JB, manufactured by Nitta Gelatin Co., Ltd.).
Furthermore, according to manufacturer information (raw material investigation document), the amount of raw material placenta in plant placenta extract is 8 times, and the amount is calculated as 8 mg of placenta per 1 mg of extract, as shown in the table.
The oral liquid compositions prepared as described above were stored at 65°C for 7 days, and the degree of precipitation was visually observed. The degree of precipitation was evaluated according to the criteria in Table 3.

As shown in Table 1, the incorporation of plant placenta extract caused precipitation, and the rate of precipitation increased as the concentration of plant placenta extract increased (Comparative Examples 1, 2-1, and 3). On the other hand, the incorporation of 0.006 w/v% or more of iron compound in terms of iron and the incorporation of collagen peptide suppressed precipitation (Examples 1 to 3). Furthermore, the precipitation suppression effect increased as the amount of iron compound increased (Examples 2-1 to 2-3).
As shown in Table 2, even at pH 4.0, precipitation occurred when plant placenta extract was added (Comparative Example 4), and the rate of precipitation increased as the concentration of plant placenta extract increased (Comparative Examples 4 and 5). However, precipitation was suppressed when an iron compound and collagen peptide were added (Examples 4-1 to 4-5). In addition, the effect was greater with increasing amounts of iron compound (Examples 4-1 to 4-3).

The present invention makes it possible to suppress precipitation derived from plant placenta extract in oral liquid compositions, and is expected to provide highly marketable oral liquid compositions containing plant placenta extract in the fields of pharmaceuticals, quasi-drugs, and foods.

Claims (8)

An oral liquid composition containing plant placenta extract, an iron compound, and collagen peptides, with the iron compound content being 0.006 to 0.2 w/v% in terms of iron. The oral liquid composition according to claim 1, wherein the iron compound is at least one selected from the group consisting of ferrous fumarate, ferric chloride, ferrous citrate, ammonium ferrous citrate, sodium ferrous citrate, ferrous gluconate, ferrous lactate, ferrous pyrophosphate, ferric pyrophosphate, ferrous sulfate, and heme iron. The oral liquid composition according to claim 1 or 2, wherein the plant placenta extract content is 0.001 to 4 w/v%. The oral liquid composition according to any one of claims 1 to 3, wherein the plant placenta extract content is 0.008 to 32 w/v% in terms of placenta. The oral liquid composition according to any one of claims 1 to 4, wherein the collagen peptide content is 0.02 to 20 w/v%. The oral liquid composition according to any one of claims 1 to 5, having a pH of 2.5 to 4.5. The oral liquid composition according to any one of claims 1 to 6, wherein the oral liquid composition is a liquid beverage. A method of suppressing precipitation that occurs when plant placenta extract is added by adding iron compounds and collagen peptides.